Methionine sulfoxide reductases and cholesterol transporter STARD3 constitute an efficient system for detoxification of cholesterol hydroperoxides.


Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
09 2023
Historique:
received: 15 09 2022
revised: 07 07 2023
accepted: 10 07 2023
medline: 23 10 2023
pubmed: 29 7 2023
entrez: 28 7 2023
Statut: ppublish

Résumé

Methionine sulfoxide reductases (MSRs) are key enzymes in the cellular oxidative defense system. Reactive oxygen species oxidize methionine residues to methionine sulfoxide, and the methionine sulfoxide reductases catalyze their reduction back to methionine. We previously identified the cholesterol transport protein STARD3 as an in vivo binding partner of MSRA (methionine sulfoxide reductase A), an enzyme that reduces methionine-S-sulfoxide back to methionine. We hypothesized that STARD3 would also bind the cytotoxic cholesterol hydroperoxides and that its two methionine residues, Met307 and Met427, could be oxidized, thus detoxifying cholesterol hydroperoxide. We now show that in addition to binding MSRA, STARD3 binds all three MSRB (methionine sulfoxide reductase B), enzymes that reduce methionine-R-sulfoxide back to methionine. Using pure 5, 6, and 7 positional isomers of cholesterol hydroperoxide, we found that both Met307 and Met427 on STARD3 are oxidized by 6α-hydroperoxy-3β-hydroxycholest-4-ene (cholesterol-6α-hydroperoxide) and 7α-hydroperoxy-3β-hydroxycholest-5-ene (cholesterol-7α-hydroperoxide). MSRs reduce the methionine sulfoxide back to methionine, restoring the ability of STARD3 to bind cholesterol. Thus, the cyclic oxidation and reduction of methionine residues in STARD3 provides a catalytically efficient mechanism to detoxify cholesterol hydroperoxide during cholesterol transport, protecting membrane contact sites and the entire cell against the toxicity of cholesterol hydroperoxide.

Identifiants

pubmed: 37507014
pii: S0021-9258(23)02127-0
doi: 10.1016/j.jbc.2023.105099
pmc: PMC10469991
pii:
doi:

Substances chimiques

Cholesterol 97C5T2UQ7J
cholesterol hydroperoxide 7J48214Z9H
Hydrogen Peroxide BBX060AN9V
Methionine AE28F7PNPL
methionine sulfoxide XN1XVI4B2C
Methionine Sulfoxide Reductases EC 1.8.4.-
Sulfoxides 0
STARD3 protein, human 0
Membrane Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

105099

Subventions

Organisme : Intramural NIH HHS
ID : ZIA HL000225
Pays : United States

Informations de copyright

Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.

Auteurs

Jung Mi Lim (JM)

Laboratory of Biochemistry, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA. Electronic address: jungmi.lim@nih.gov.

Venkata R Sabbasani (VR)

Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, Rockville, Maryland, USA.

Rolf E Swenson (RE)

Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, Rockville, Maryland, USA.

Rodney L Levine (RL)

Laboratory of Biochemistry, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH